Literature DB >> 15903021

TNF-alpha -308 promoter polymorphism in patients with rheumatoid arthritis.

A Pawlik1, M Florczak, L Ostanek, M Brzosko, I Brzosko, B Gawronska Szklarz.   

Abstract

OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disease in which tumour necrosis factor-alpha (TNF-alpha) plays an important role. There are, however, controversial reports that TNF-alpha promoter polymorphism may be an independent marker of susceptibility and severity of RA. The aim of the present study was to examine the TNF-alpha -308 promoter polymorphism in patients with RA.
METHODS: We examined 91 patients with RA diagnosed according to the criteria of the American College of Rheumatology. Polymerase chain reaction (PCR) amplification was used for analysis of the polymorphism at position -308 in promoter of TNF-alpha gene.
RESULTS: Distribution of TNF-alpha genotypes in RA patients did not differ from that in control subjects. Moreover, there was no association between TNF-alpha genotypes and age at disease diagnosis, disease activity in global physician's assessment, and joint and extra-articular involvement. There was also no correlation between TNF-alpha polymorphism and disease activity measures, including erythrocyte sedimentation rate (ESR), CRP, number of swollen and tender joints, and morning stiffness duration.
CONCLUSIONS: We suggest that TNF-alpha -308 promoter polymorphism is not a genetic risk factor for RA susceptibility and severity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15903021

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  8 in total

1.  Tumour necrosis factor a -308 promoter polymorphism in patients with rheumatoid arthritis.

Authors:  Zahra Rezaieyazdi; Jalil Tavakol Afshari; Mahnaz Sandooghi; Farnaz Mohajer
Journal:  Rheumatol Int       Date:  2007-08-29       Impact factor: 2.631

2.  Polymorphism in the tumor necrosis factor-alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population.

Authors:  Petr Nemec; Monika Pavkova-Goldbergova; Martina Stouracova; Anna Vasku; Miroslav Soucek; Jindra Gatterova
Journal:  Clin Rheumatol       Date:  2007-06-12       Impact factor: 2.980

3.  MMP-2, TNF-α and NLRP1 polymorphisms in Chinese patients with ankylosing spondylitis and rheumatoid arthritis.

Authors:  Rongbin Sun; Yong Huang; Hui Zhang; Ruiping Liu
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

4.  Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis?

Authors:  Alessia Ongaro; Monica De Mattei; Agnese Pellati; Angelo Caruso; Stefano Ferretti; Federica Francesca Masieri; Maria Fotinidi; Ilaria Farina; Francesco Trotta; Melissa Padovan
Journal:  Rheumatol Int       Date:  2008-02-29       Impact factor: 2.631

Review 5.  Association between TNF-α promoter -308 A/G polymorphism and rheumatoid arthritis: a meta-analysis.

Authors:  Gwan Gyu Song; Sang-Cheol Bae; Jae-Hoon Kim; Young Ho Lee
Journal:  Rheumatol Int       Date:  2013-12-05       Impact factor: 2.631

6.  TNF-α and TNF-β Gene Polymorphism in Saudi Rheumatoid Arthritis Patients.

Authors:  Hannan Al-Rayes; Ramiz Al-Swailem; Maysson Albelawi; Misbahul Arfin; Abdulrahman Al-Asmari; Mohammad Tariq
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2011-06-14

7.  Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis.

Authors:  Erik J M Toonen; Pilar Barrera; Jaap Fransen; Arjan P M de Brouwer; Agnes M Eijsbouts; Pierre Miossec; Hubert Marotte; Hans Scheffer; Piet L C M van Riel; Barbara Franke; Marieke J H Coenen
Journal:  Arthritis Res Ther       Date:  2012-12-07       Impact factor: 5.156

8.  Lack of association or interactions between the IL-4, IL-4Ralpha and IL-13 genes, and rheumatoid arthritis.

Authors:  Ioanna Marinou; Simon H Till; David J Moore; Anthony G Wilson
Journal:  Arthritis Res Ther       Date:  2008-07-14       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.